Baker Bros. Advisors’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,000,000
| Closed | -$1.47M | – | 127 |
|
|
2022
Q2 | $1.47M | Hold |
1,000,000
| – | – | 0.01% | 99 |
|
|
2022
Q1 | $1.15M | Buy |
+1,000,000
| New | +$1.63M | 0.01% | 106 |
|
|
2018
Q1 | – | Sell |
-232,481
| Closed | -$2.92M | – | 122 |
|
|
2017
Q4 | $2.92M | Hold |
232,481
| – | – | 0.03% | 91 |
|
|
2017
Q3 | $4.43M | Hold |
232,481
| – | – | 0.04% | 79 |
|
|
2017
Q2 | $3.51M | Hold |
232,481
| – | – | 0.03% | 71 |
|
|
2017
Q1 | $3.99M | Hold |
232,481
| – | – | 0.03% | 72 |
|
|
2016
Q4 | $2.81M | Hold |
232,481
| – | – | 0.03% | 80 |
|
|
2016
Q3 | $2.29M | Hold |
232,481
| – | – | 0.02% | 93 |
|
|
2016
Q2 | $2.38M | Hold |
232,481
| – | – | 0.03% | 93 |
|
|
2016
Q1 | $2.82M | Hold |
232,481
| – | – | 0.03% | 89 |
|
|
2015
Q4 | $3.72M | Hold |
232,481
| – | – | 0.03% | 87 |
|
|
2015
Q3 | $2.99M | Hold |
232,481
| – | – | 0.03% | 90 |
|
|
2015
Q2 | $5.58M | Hold |
232,481
| – | – | 0.05% | 73 |
|
|
2015
Q1 | $4.37M | Buy |
232,481
+30,518
| +15% | +$630K | 0.04% | 78 |
|
|
2014
Q4 | $3.81M | Sell |
201,963
-12,049
| -6% | -$281K | 0.04% | 81 |
|
|
2014
Q3 | $5.8M | Hold |
214,012
| – | – | 0.07% | 57 |
|
|
2014
Q2 | $6.66M | Hold |
214,012
| – | – | 0.08% | 58 |
|
|
2014
Q1 | $4.87M | Sell |
214,012
-5,988
| -3% | -$182K | 0.06% | 72 |
|
|
2013
Q4 | $4.58M | Buy |
220,000
+200,000
| +1,000% | +$5.8M | 0.06% | 68 |
|
|
2013
Q3 | $800K | Hold |
20,000
| – | – | 0.01% | 79 |
|
|
2013
Q2 | $563K | Buy |
+20,000
| New | +$514K | 0.01% | 71 |
|
Other funds holding EPZM
Baker Bros. Advisors's EPZM Position: Q3 2022 in Review
Baker Bros. Advisors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 1,000,000 shares — an estimated $1.47M sold.
Baker Bros. Advisors first reported a position in EPZM in Q2 2013 and held it in 21 quarters. The position peaked at $6.66M in Q2 2014. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Baker Bros. Advisors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Baker Bros. Advisors sold 1,000,000 Epizyme, Inc shares in Q3 2022, an estimated $1.47M.
- Baker Bros. Advisors first reported a position in Epizyme, Inc in Q2 2013 and held it in 21 quarters.
- Baker Bros. Advisors's Epizyme, Inc position peaked at $6.66M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.